Skip to main content

Table 3 Assessment of the percentage of cell types expressing TNFα in patients with NSCLC in above median survival patients in the islets (AMSI) and stroma (AMSS) and below median survival patients in the islets (BMSI) and stroma (BMSS).

From: Tumour necrosis factor-alpha expression in tumour islets confers a survival advantage in non-small cell lung cancer

  AMSI AMSS BMSI BMSS
% of cells which were Macrophages 61.8*
(9.4-100)
76.9†
(16.6-100)
22.2
(5-71.5)
39.7
(0-61.9)
% of cells which were mast cells 45.2#
(20.3-58.4)
54.9¶
(0-79.1)
5.6
(0-100)
10.5
(0-55)
Estimated % of other cell types 0 0 72 50
  1. *p < 0.001 compared to BMSI; †p < 0.001 compared to BMSS; #p < 0.001 compared to BMSI; ¶p < 0.001 compared to BMSS. We analysed the cellular distribution of TNFα expressed by mast cells in the subset of samples previously stained for macrophage-TNFα [25].